I'm an expert in crafting public health messages: Here are 3 marketing strategies I use to make Philadelphia healthier
In Philadelphia, the leading causes of death are heart disease, cancer and unintentional drug overdose. While some of these deaths are caused by things out of our control – like genetics – many are largely preventable.
Preventable deaths are the result of a series of decisions. Whether a person decides to smoke, eat lots of fried foods or be a couch potato, their decisions – sometimes unconsciously – can affect their health.
I'm a health communication expert and public health researcher at Temple University in North Philadelphia. I began working in public health in the late 1980s at the beginning of the HIV/AIDS epidemic, and before that I worked in marketing and public relations. I have spent my career thinking about how health decisions are like many of the decisions consumers make each day around which products to buy.
One key difference with health decisions is the inherent risks involved. There isn't much risk in trying a new brand of cereal, but there is risk in riding a motorcycle without a helmet.
Many people have a 'that won't happen to me' attitude when making a decision that involves risk. This element of 'risk perception' has guided my interest in health decisions and how to use commercial marketing techniques – the same ones companies use to sell products – to encourage people to get vaccinated, get a colonoscopy or get treated for a medical condition.
One strategy I use is segmentation analysis.
Segmentation analysis is the process of looking at groups of people who may look like they are all similar on the surface – such as Black women from North Philadelphia – and then breaking them into smaller groups based on differences in their attitudes, beliefs or behaviors.
Looking at these 'psychographics' instead of demographics like age or sex can help public health communication researchers better understand how to communicate effectively.
For example, I led a study in 2021 that looked at how connected transgender women living in Philadelphia and the San Francisco Bay Area felt to other members of the trans community. We wanted to see if messaging about PrEP, or pre-exposure prophylaxis, the medication used to prevent HIV infection, would need to be different depending on how connected they felt.
We found that participants who were more engaged with the trans community were not only more knowledgeable about PrEP, but they were also more likely to see the benefits of using it compared with those who were less engaged.
This indicates that strategies to reach those not as connected may need to include, for example, providing more basic information about what PrEP is and how it works.
Another powerful marketing tool that I use is a process known as perceptual mapping and vector message modeling.
Using simple survey answers, we can mathematically model how people are thinking about a health decision and present it in a three-dimensional map.
Similar to how someone might think about the relationship between where cities or countries are in relation to each other – such as where Philadelphia is in relation to New York or Chicago – we can take answers from a survey and convert them into distances. We ask people to agree or disagree to statements about the benefits or barriers to a decision and enter their responses into a computer program to create the map.
We can then do vector message modeling, which shows how to move the group toward the desired decision.
Think back to high school physics when you may have learned about the amount of force, or pushing and pulling, needed to move one object toward another. Vector message modeling helps us figure out which beliefs to push or pull against to get the group to move toward a particular decision, and it helps us create the most persuasive messages for that group.
When we use vector modeling along with segmentation analysis, we can also compare how messaging may need to be similar or different for different groups.
For example, I used segmentation analysis and then perceptual mapping and vector message modeling to understand how medical mistrust might affect the decision to get vaccinated for COVID-19 among a group of Philadelphians who had not yet been vaccinated.
Our team then looked at perceptual maps and vector message modeling by levels of mistrust. The vectors showed that those with high levels of medical mistrust would be more likely to respond to messages that addressed concerns about the pandemic being a hoax, or the worry that minorities wouldn't get the same treatment as others.
This allowed us to think about how to build in messages around those issues in public media campaigns or other communication strategies that encourage vaccination.
I have used these methods to create and test a number of different communication strategies to influence health decisions.
For example, I've developed web-based tools that have been used in hospitals and clinics in Philadelphia to encourage methadone patients with hepatitis C to receive antiviral treatment for their infection, Black cancer patients to take part in a clinical trial or to get genetic testing, and patients with low literacy and higher risk of colorectal cancer to have a colonoscopy.
My colleagues and I have also developed posters, booklets and social media posts that encourage low-income and vaccine-hesitant Philadelphians in Kensington to get COVID-19 booster shots; educational slides for low-literacy Philadelphia adults on dirty bombs and how the radioactive weapons might be used in a terror attack; and a comic book for trans women to learn about the benefits of PrEP use.
Getting people to make better decisions about their health can be an uphill battle. We all have our reasons for not doing things that are good for us. For example, what did you eat for lunch today? Was it healthy? If not, why did you eat it?
My job is to figure out what makes people do what they do, and then help them make decisions that keep them healthy.
Read more of our stories about Philadelphia.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Sarah Bauerle Bass, Temple University
Read more:
Philly residents with opioid addiction get medication from the 'bupe bus' − creating a path for treatment
Immigrant moms feel unsafe and unheard when seeking pregnancy care – here's how they'd improve Philly's health care system
Mpox, AIDS and COVID-19 show the challenges of targeting public health messaging to specific groups without causing stigma
Sarah Bauerle Bass has received funding from a number of organizations, including the National Institutes of Health, the American Cancer Society, Pennsylvania and Philadelphia Departments of Health, and independent pharma research grants from Gilead and Merck.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data